Post by Sanofi

Results from our phase 3 study show our Pompe disease treatment met its primary endpoint in treatment-naïve infants with infantile-onset Pompe disease (IOPD). These results offer important progress for a highly vulnerable patient population. Read the full announcement: https://lnkd.in/d-xWsKv3